Evaluation of the effects of occlusal splint and masseter muscle injection in patients with myofascial pain: a randomised controlled trial

Myofascial pain is one of the common symptoms in patients with temporomandibular joint disorders (TMD). Occlusal splint (OS) and masticatory muscle trigger point (TP) local injections are primary treatment options. We aimed to investigate the effects of these treatments using clinical and elastography measures. Patients who were diagnosed with myofascial pain according to Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) were included. There were 16 patients in each group. Group 1 was treated with occlusal splint, Group 2 was treated with occlusal splint and masseter muscle lidocaine injection, Group 3 was treated with masseter muscle lidocaine injection and Group 4 consisted of healthy volunteers. Degree of pain and maximum mouth opening (MMO) were recorded. Masseter muscle stiffness was evaluated by Shear wave elastography. Measurements were repeated at 1st and 3rd months of post-treatment. Pain decreased at all times in all the patients (p = 0.001). Pain in Group 2 and Group 3 approached 0 level at 3rd month. MMO increased from baseline to 1st month and from 1st month to 3rd month and masseter stiffness decreased from baseline to 1st month and to 3rd month (p = 0.001) in all groups. Occlusal splint and masseter muscle lidocaine injection were effective in reducing pain and increasing MMO in patients with myofascial pain. All treatments reduced masseter muscle stiffness. All the treatment modalities had clinically similar and successful outcomes.

Masseter muscle; Masticatory muscle disorders; Occlusal splint; Shear wave elastography; Temporomandibular disorders; Trigger point injection

[1] Okeson JP. Management of temporomandibular disorders and occlusion. 8th edn. Elsevier Mosby: St. Louis, USA. 2019.

[2] Buescher JJ. Temporomandibular joint disorders. American Family Physician. 2007; 76: 1477–1482.

[3] Chaurand J, Pacheco-Ruíz L, Orozco-Saldívar H, López-Valdés J. Efficacy of botulinum toxin therapy in treatment of myofascial pain. Journal of Oral Science. 2017; 59: 351–356.

[4] Costa YM, Ariji Y, Ferreira DMAO, Bonjardim LR, Conti PCR, Ariji E, et al. Muscle hardness and masticatory myofascial pain: assessment and clinical relevance. Journal of Oral Rehabilitation. 2018; 45: 640–646.

[5] Takashima M, Arai Y, Kawamura A, Hayashi T, Takagi R. Quantitative evaluation of masseter muscle stiffness in patients with temporomandibular disorders using shear wave elastography. Journal of Prosthodontic Research. 2017; 61: 432–438.

[6] Murayama M, Watanabe K, Kato R, Uchiyama T, Yoneda T. Association of muscle hardness with muscle tension dynamics: a physiological property. European Journal of Applied Physiology. 2012; 112: 105–112.

[7] Fricton JR. Masticatory myofascial pain: an explanatory model integrating clinical, epidemiological and basic science research. Bull Group Int Rech Sci Stomatol Odontol. 1999; 41: 14–25.

[8] Lickteig R, Lotze M, Kordass B. Successful therapy for temporomandibular pain alters anterior insula and cerebellar representations of occlusion. Cephalalgia. 2013; 33: 1248–1257.

[9] Sikdar S, Shah JP, Gebreab T, Yen R, Gilliams E, Danoff J, et al. Novel applications of ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue. Archives of Physical Medicine and Rehabilitation. 2009; 90: 1829–1838.

[10] D’Orsi GM, Via AG, Frizziero A, Oliva F. Treatment of adhesive capsulitis: a review. Muscles, Ligaments and Tendons Journal. 2012; 2: 70–78.

[11] Chino K, Akagi R, Dohi M, Fukashiro S, Takahashi H. Reliability and validity of quantifying absolute muscle hardness using ultrasound elastography. PLOS ONE. 2012; 7: e45764.

[12] Adigozali H, Shadmehr A, Ebrahimi E, Rezasoltani A, Naderi F. Ultrasonography for the assessment of the upper trapezius properties in healthy females: a reliability study. Muscles, Ligaments and Tendons Journal. 2016; 6: 167–172.

[13] Ohrbach R. Diagnostic criteria for temporomandibular disorders: assessment instruments. 2016. Available at: www.rdc-tmdinternational.org (Accessed: 17 October 2022).

[14] Ozkan F, Cakir Ozkan N, Erkorkmaz U. Trigger point injection therapy in the management of myofascial temporomandibular pain. Agri. 2011; 23: 119–125.

[15] Nitecka-Buchta A, Walczynska-Dragon K, Batko-Kapustecka J, Wieckiewicz M. Comparison between collagen and lidocaine intramuscular injections in terms of their efficiency in decreasing myofascial pain within masseter muscles: a randomized, single-blind controlled trial. Pain Research and Management. 2018; 2018: 8261090.

[16] Raphael KG, Marbach JJ, Klausner JJ, Teaford MF, Fischoff DK. Is bruxism severity a predictor of oral splint efficacy in patients with myofascial face pain? Journal of Oral Rehabilitation. 2003; 30: 17–29.

[17] Turk DC, Zaki HS, Rudy TE. Effects of intraoral appliance and biofeedback/stress management alone and in combination in treating pain and depression in patients with temporomandibular disorders. The Journal of Prosthetic Dentistry. 1993; 70: 158–164.

[18] Dworkin SF, Turner JA, Wilson L, Massoth D, Whitney C, Huggins KH, et al. Brief group cognitive-behavioral intervention for temporomandibular disorders. Pain. 1994; 59: 175–187.

[19] Dimitroulis G, Gremillion HA, Dolwick MF, Walter JH. Temporomandibular disorders. 2. Non-surgical treatment. Australian Dental Journal. 1995; 40: 372–376.

[20] Kuttila M, Le Bell Y, Savolainen-Niemi E, Kuttila S, Alanen P. Efficiency of occlusal appliance therapy in secondary otalgia and temporomandibular disorders. Acta Odontologica Scandinavica. 2002; 60: 248–254.

[21] Davies SJ, Gray RJ. The pattern of splint usage in the management of two common temporomandibular disorders. Part III: long-term follow-up in an assessment of splint therapy in the management of disc displacement with reduction and pain dysfunction syndrome. British Dental Journal. 1997; 183: 279–283.

[22] Minakuchi H, Kuboki T, Matsuka Y, Maekawa K, Yatani H, Yamashita A. Randomized controlled evaluation of non-surgical treatments for temporomandibular joint anterior disk displacement without reduction. Journal of Dental Research. 2001; 80: 924–928.

[23] Raeissadat SA, Rayegani SM, Sadeghi F, Rahimi-Dehgolan S. Comparison of ozone and lidocaine injection efficacy vs dry needling in myofascial pain syndrome patients. Journal of Pain Research. 2018: 11: 1273–1279.

[24] Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, et al. Analgesic effects of botulinum toxin a: a randomized, placebo-controlled clinical trial. Developmental Medicine & Child Neurology. 2000; 42: 116–121.

[25] Kim PS. Role of injection therapy: review of indications for trigger point injections, regional blocks, facet joint injections, and intra-articular injections. Current Opinion in Rheumatology. 2002; 14: 52–57.

[26] Schulte-Mattler WJ, Krack P; BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin a: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004; 109: 110–114.

[27] McMillan AS, Nolan A, Kelly PJ. The efficacy of dry needling and procaine in the treatment of myofascial pain in the jaw muscles. American Journal of Orthodontics and Dentofacial Orthopedics. 1999; 115: 307–314.

[28] Niamtu J 3rd. Botulinum toxin a: a review of 1,085 oral and maxillofacial patient treatments. Journal of Oral and Maxillofacial Surgery. 2003; 61: 317–324.

[29] Karadaş Ö, Gül HL, Inan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. the Journal of Headache and Pain. 2013; 14: 44.

[30] Bilici IŞ, Emes Y, Aybar B, Yalçın S. Evaluation of the effects of occlusal splint, trigger point injection and arthrocentesis in the treatment of internal derangement patients with myofascial pain disorders. Journal of Cranio-Maxillofacial Surgery. 2018; 46: 916–922.

[31] Naikmasur V, Bhargava P, Guttal K, Burde K. Soft occlusal splint therapy in the management of myofascial pain dysfunction syndrome: a follow-up study. Indian Journal of Dental Research. 2008; 19: 196–203.

[32] Suvinen T, Reade P. Prognostic features of value in the management of temporomandibular joint pain-dysfunction syndrome by occlusal splint therapy. The Journal of Prosthetic Dentistry. 1989; 61: 355–361.

[33] Ekberg E, Vallon D, Nilner M. The efficacy of appliance therapy in patients with temporomandibular disorders of mainly myogenous origin. A randomized, controlled, short-term trial. Journal of Oral & Facial Pain and Headache. 2003; 17: 133–139.

[34] Chung S, Kim H. The Effect of the stabilization splint on the TMJ closed lock. CRANIO®. 1993; 11: 95–101.

[35] Wong Y, Cheng J. A case series of temporomandibular disorders treated with acupuncture, occlusal splint and point injection therapy. Acupuncture in Medicine. 2003; 21: 138–149.

[36] Poveda Roda R, Bagan J V, Díaz Fernández JM, Hernández Bazán S, Jiménez Soriano Y. Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors. Med Oral Patol Oral Cir Bucal. 2007: 12: E292–E298.

[37] Olchowy A, Wieckiewicz M, Winocur E, Dominiak M, Dekkers I, Łasecki M, et al. Great potential of ultrasound elastography for the assessment of the masseter muscle in patients with temporomandibular disorders. a systematic review. Dentomaxillofacial Radiology. 2020; 49: 20200024.

[38] Arda K, Ciledag N, Aktas E, Arıbas BK, Köse K. Quantitative assessment of normal soft-tissue elasticity using shear-wave ultrasound elastography. American Journal of Roentgenology. 2011; 197: 532–536.

[39] Herman J, Sedlackova Z, Vachutka J, Furst T, Salzman R, Vomacka J. Shear wave elastography parameters of normal soft tissues of the neck. Biomedical Papers. 2017; 161: 320–325.

[40] Habibi HA, Ozturk M, Caliskan E, Turan M. Quantitative assessment of temporomandibular disc and masseter muscle with shear wave elastography. Oral Radiology. 2022; 38: 49–56.

[41] Dioguardi Burgio M, Grégory J, Ronot M, Sartoris R, Chatellier G, Vilgrain V; Group SSI-SWE. 2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting. Insights into Imaging. 2021; 12: 145.